Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Palladone SR capsules 8 mg

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Hydromorphone hydrochloride may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Hydromorphone hydrochloride
Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for This medicine has been prescribed for you for the relief of severe pain. It contains hydromorphone, which belongs to a class of medicines called opioids, which are 'pain relievers'. The medicine has been prescribed for you and should not be given to anyone else. Opioids can cause addiction and you may get withdrawal symptoms if you stop taking it suddenly. Your doctor should have explained how long you will be taking it for and when it is appropriate to stop, how to do this safely.

What you need to know before you take it

e Palladone SR capsules Do not take Palladone SR capsules if you:

  • are allergic to hydromorphone or to any of the other ingredients of the capsules (listed in section 6);
  • have breathing problems, such as severe chronic obstructive airways disease, respiratory depression or severe asthma. Symptoms may include breathlessness, coughing or breathing more slowly and weakly than expected;
  • have a severe pain in your abdomen;
  • have liver problems;
  • have a condition where the small bowel does not work properly (paralytic ileus);
  • are taking a type of medicine known as a monoamine oxidase inhibitor (examples include tranylcypromine, phenelzine, isocarboxazid, moclobemide and linezolid), or you have taken this type of medicine in the last two weeks;
  • are under 12 years of age. If you are going to have an operation, or have just had an operation, please tell the doctor at the hospital that you are taking these capsules. Your doctor may adjust your treatment. These

tablets/capsules should not be used for short-term pain after an operation owing to the increased risk of dependence and breathlessness. Warnings and precautions Talk to your doctor or pharmacist before taking this medicine if you:

  • have previously suffered from withdrawal symptoms such as agitation, anxiety, shaking or sweating when you have stopped taking alcohol or drugs;
  • feel you need to take more Palladone SR capsules to get the same level of pain relief, this may mean you are becoming tolerant to the effects of this medicine or are becoming addicted to it. Speak to your doctor who will discuss your treatment and may change your dose or switch you to an alternative pain reliever;
  • have breathing problems, such as severely impaired pulmonary function, chronic obstructive airways disease or reduced respiratory reserve. Your doctor will have told you if you have any of these conditions. Symptoms may include breathlessness and coughing;
  • have a severe headache or feel sick due to a head injury or increased pressure in your skull (for instance due to brain disease). This is because the capsules may make symptoms worse or hide the extent of a head injury;
  • suffer from seizures, fits or convulsions;
  • have a mental disorder as a result of an infection (toxic psychosis);
  • have inflammation of the pancreas (which causes severe pain in the abdomen and back);
  • have an under-active thyroid gland (hypothyroidism);
  • have low blood pressure (hypotension);
  • have kidney problems;
  • have poor adrenal gland function (your adrenal gland is not working properly which may cause symptoms including weakness, weight loss, dizziness, feeling or being sick);
  • have prostate problems;
  • are suffering from shock (this may make you suddenly feel very lightheaded, faint, cold or clammy and look pale).
  • suffer from constipation. This medicine may cause breathing problems or worsen already existing problems while sleeping. These problems may include pauses in breathing during sleep, being awoken by shortness of breath, difficulty staying asleep or excessive daytime drowsiness. If you or someone else observes these symptoms contact your doctor. Your doctor may want to lower your dose. Tolerance, dependence and addiction This medicine contains hydromorphone, which is an opioid. It can cause dependence and/or addic on. This medicine contains hydromorphone which is an opioid medicine. Repeated use of opioid painkillers may result in the drug being less effective (you become accustomed to it). Repeated use of Palladone SR capsules may lead to dependence and abuse which may result in life threatening overdose. If you have concern that you may become dependent on Palladone SR capsules, it is important that you consult your doctor. Taking this medicine regularly, particularly for a long time, can lead to addiction. Your doctor should have explained how long you will be using it for and when it is appropriate to stop, how to do this safely. Dependence or addiction can make you feel that you are no longer in control of how much medicine you need to take or how often you need to take it.

The risk of becoming dependent or addicted varies from person to person. You may have a greater risk of becoming dependent or addicted on Palladone SR if: –

You or anyone in your family have ever abused or been dependent on alcohol, prescription medicines or illegal drugs ("addiction"). You are a smoker. You have ever had problems with your mood (depression, anxiety or a personality disorder) or have been treated by a psychiatrist for other mental illnesses.

If you notice any of the following signs whilst taking Palladone SR, it could be a sign that you have become dependent or addicted: –

You need to take the medicine for longer than advised by your doctor. You need to take more than the recommended dose. You might feel that you need to carry on taking your medicine, even when it doesn't help to relieve your pain. You are using the medicine for reasons other than prescribed, for instance, 'to stay calm' or 'help you sleep'. You have made repeated, unsuccessful attempts to quit or control the use of the medicine. When you stop taking the medicine you feel unwell, and you feel better once taking the medicine again ('withdrawal effects').

If you notice any of these signs, speak to your doctor to discuss the best treatment pathway for you, including when it is appropriate to stop and how to stop safely (see section 3, If you stop taking { Palladone SR}). Rarely, increasing the dose of this medicine can make you more sensitive to pain. If this happens, you need to speak to your doctor about your treatment. Addiction can cause withdrawal symptoms when you stop taking this medicine. Withdrawal symptoms can include restlessness, difficulty sleeping, irritability, agitation, anxiety, feeling your heartbeat (palpitations), increased blood pressure, feeling or being sick, diarrhoea, loss of appetite, shaking, shivering or sweating. Your doctor will discuss with you how to gradually reduce your dose before stopping the medicine. It is important that you do not stop taking the medicine suddenly as you will be more likely to experience withdrawal symptoms. Opioids should only be used by those they are prescribed for. Do not give your medicine to anyone else. Taking higher doses or more frequent doses of opioid may increase the risk of addiction. Overuse and misuse can lead to overdose and/or death. You may experience hormonal changes while taking these capsules. Your doctor may want to monitor these changes. Other medicines and Palladone SR capsules Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. If you take these capsules with some other medicines, the effect of the capsules or the other medicine may be changed. These capsules must not be used together with a type of medicine known as a monoamine oxidase inhibitor, or if you have taken this type of medicine in the last two weeks (see section 2 'Do not take…').

Tell your doctor or pharmacist if you are taking:

  • medicines to help you sleep or stay calm (for example benzodiazepines, tranquillisers, hypnotics or sedatives);
  • medicines known as barbiturates to either treat fits or to help you sleep;
  • medicines to stop you feeling or being sick;
  • medicines to treat depression;
  • medicines to treat psychiatric or mental disorders (such as neuroleptics);
  • other strong analgesics or 'painkillers'. Also tell your doctor if you have recently been given an anaesthetic. Concomitant use of Palladone SR capsules and sedative medicines such as benzodiazepines or related drugs increases the risk of drowsiness, difficulties in breathing (respiratory depression), coma and may be life-threatening. Because of this, concomitant use should only be considered when other treatment options are not possible. The concomitant use of opioids and drugs used to treat epilepsy, nerve pain or anxiety (gabapentin and pregabalin) increases the risk of opioid overdose, respiratory depression and may be life-threatening. However if your doctor does prescribe Palladone SR capsules together with sedative medicines the dose and duration of concomitant treatment should be limited by your doctor. Please tell your doctor about all sedative medicines you are taking, and follow your doctor's dose recommendation closely. It could be helpful to inform friends or relatives to be aware of the signs and symptoms stated above. Contact your doctor when experiencing such symptoms. Sleep-related breathing disorders Palladone SR capsules can cause sleep-related breathing disorders such as sleep apnea (breathing pauses during sleep) and sleep related hypoxemia (low oxygen level in the blood). The symptoms can include breathing pauses during sleep, night awakening due to shortness of breath, difficulties to maintain sleep or excessive drowsiness during the day. If you or another person observe these symptoms, contact your doctor. A dose reduction may be considered by your doctor. Palladone SR capsules with alcohol Drinking alcohol whilst taking Palladone SR capsules may make you feel more sleepy or increase the risk of serious side effects such as shallow breathing with a risk of stopping breathing, and loss of consciousness. It is recommended not to drink alcohol whilst you are taking Palladone SR capsules. Pregnancy and breastfeeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine. Pregnancy Do not take Palladone SR capsules if you are pregnant or think you might be pregnant unless you have discussed this with your doctor and the benefits of treatment are considered to outweigh the potential harm to the baby. If you take Palladone SR capsules during pregnancy your baby may become dependent and experience withdrawal symptoms after the birth which may need to be treated, such as high-pitched cry, jitteriness, fits, poor feeding and diarrhoea. Breast-feeding Do not take Palladone SR capsules while you are breastfeeding as hydromorphone passes into breast milk and will affect your baby.

Driving and using machines These capsules may cause a number of side effects such as drowsiness, which could affect your ability to drive or use machinery (see section 4 for a full list of side effects). These are usually most noticeable when you first start taking the capsules, or when changing to a higher dose. If you are affected you should not drive or use machinery. This medicine can affect your ability to drive as it may make you sleepy or dizzy.

  • Do not drive while taking this medicine until you know how it affects you.
  • It is an offence to drive while you have this medicine in your body over a specified limit unless you have a defence (called the 'statutory defence').
  • This defence applies when: o The medicine has been prescribed to treat a medical or dental problem; and o You have taken it according to the instructions given by the prescriber and in the information provided with the medicine.
  • Please note that it is still an offence to drive if you are unfit because of the medicine (i.e. your ability to drive is being affected). Details regarding a new driving offence concerning driving after drugs have been taken in the UK may be found here: https://www.gov.uk/drug-driving-law. Talk to your doctor or pharmacist if you are not sure whether it is safe for you to drive while taking this medicine.

How to take it

Palladone SR capsules Always take the capsules exactly as your doctor has told you. The label on your medicine will tell you how many capsules to take and how often. Adults and children over 12 years of age The usual starting dose is one 4 mg capsule every 12 hours. However, your doctor will prescribe the dose required to treat your pain. If you find that you are still in pain whilst taking these capsules, discuss this with your doctor. Children under 12 years of age Children under 12 years of age should not take the capsules. Do not exceed the dose recommended by your doctor. You should check with your doctor or pharmacist if you are not sure. Your doctor should have discussed with you how long the course of Palladone SR capsules will last. They will arrange a plan for stopping treatment. This will outline how to gradually reduce the dose and stop taking the medicine. Swallow your capsules whole with a glass of water. If you prefer, you can open the capsules and sprinkle the contents on to cold soft food, such as yoghurt. You must only take the capsules by mouth. Do not crush or chew the capsule or the capsule contents. Palladone SR capsules are designed to work properly over 12 hours. If the capsule contents are crushed, dissolved or chewed, the entire 12-hour dose may be absorbed rapidly into your body.

The capsule contents should never be injected. This can be dangerous, causing serious problems such as an overdose, which may be fatal. You should take your capsules every 12 hours. For instance, if you take a capsule at 8 o'clock in the morning, you should take your next capsule at 8 o'clock in the evening. If you take more Palladone SR capsules than you should or if someone accidentally swallows your capsules Call your doctor or hospital straight away as you may need emergency treatment in hospital. People who have taken an overdose may feel very sleepy, sick, dizzy, result in a brain disorder (known as toxic leukoencephalopathy) or get pneumonia from inhaling vomit or foreign matter (symptoms may include breathlessness, cough and fever). They may also have breathing difficulties leading to unconsciousness, or even death. When seeking medical attention make sure that you take this leaflet and any remaining capsules with you to show the doctor. If you forget to take Palladone SR capsules If you remember within 4 hours of the time your capsule was due, take your capsule straight away. Take your next capsule at your normal time. If you are more than 4 hours late, please call your doctor or pharmacist for advice. Do not take a double dose to make up for a forgotten capsule. If you stop taking Palladone SR capsules Do not suddenly stop taking this medicine. If you want to stop taking this medicine discuss this with your doctor first. They will tell you how to do this, usually by reducing the dose gradually so that any unpleasant withdrawal effects are kept to a minimum. Withdrawal symptoms such as restlessness, difficulty sleeping, irritability, agitation, anxiety, feeling your heartbeat (palpitations), increased blood pressure, feeling or being sick, diarrhoea, shaking, shivering or sweating may occur if you suddenly stop taking this medicine. If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 4. Possible side effects Like all medicines, these capsules can cause side effects, although not everybody gets them. This medicine can cause allergic reactions. The incidence of serious allergic reactions is not known. Tell your doctor immediately if you get any sudden wheeziness, difficulties in breathing, swelling of the eyelids, face or lips, mouth or throat, or any rash or itching especially those covering your whole body. The most serious side effect is a condition where you breathe more slowly or weakly than expected (respiratory depression). Drug withdrawal When you stop taking Palladone SR capsules you may experience drug withdrawal symptoms, which include restlessness, difficulty sleeping, irritability, agitation, anxiety, feeling your heartbeat (palpitations), increased blood pressure, feeling or being sick, diarrhoea, shaking, shivering or sweating. How do I know if I am addicted?

If you notice any of the following signs whilst taking Palladone SR capsules it could be a sign that you have become addicted.

  • You need to take the medicine for longer than advised by your prescriber;
  • You feel you need to use more than the recommended dose;
  • You are using the medicine for reasons other than prescribed;
  • When you stop taking the medicine you feel unwell, and you feel better once taking the medicine again. If you notice any of these signs it is important you talk to your doctor. Most people will have constipation when using this medicine. Increasing the amount of fibre (fruit, vegetables, wholemeal bread, pasta, brown rice) and fluids you eat and drink may help reduce the problem, but if necessary your doctor may prescribe a laxative. You may feel sick or vomit (be sick) when you use this medicine, this should normally wear off after a few days however your doctor can prescribe an anti-vomiting medicine if it continues to be a problem. Very common side effects (may affect more than 1 in 10 people)
  • Dizziness, constipation, feel sick.
  • Drowsiness (this is most likely when you first start taking your capsules or when your dose is increased, but it should wear off after a few days). Common side effects (may affect up to 1 in 10 people)
  • Loss of appetite.
  • Confusion, anxiety, difficulty sleeping.
  • Headache.
  • Being sick, abdominal pain, dry mouth.
  • A feeling of unusual weakness.
  • Itchy skin, sweating. Uncommon side effects (may affect up to 1 in 100 people)
  • Agitation, depression, hallucinations, nightmares.
  • A feeling of extreme happiness.
  • Muscle spasms, shaking, tingling in the hands or feet.
  • Blurred vision.
  • Low blood pressure.
  • Shortness of breath.
  • Diarrhoea, changes in taste.
  • A worsening in liver function tests (seen in a blood test)
  • Rash.
  • Difficulty in passing urine.
  • Impotence.
  • Withdrawal symptoms (see section 'Drug withdrawal').
  • Tiredness, generally feeling unwell.
  • Swelling of the hands, ankles or feet. Rare side effects (may affect up to 1 in 1,000 people)
  • Sedation, lack of energy.
  • Fast heartbeat.
  • A condition where you breathe more slowly and weakly than expected.

Possible side effects

with unknown frequency (frequency cannot be estimated from the available data)

  • Allergic reactions.
  • Dependence and addiction (see section 'How do I know if I am addicted?')
  • Drug tolerance
  • Unpleasant or uncomfortable mood.
  • Reduction in size of the pupils in the eye.
  • An increase in sensitivity to pain (hyperalgesia; see "Warnings and precautions" in section 2).
  • Seizures, fits or convulsions.
  • Uncontrolled muscle movements.
  • Facial flushing (redness of the face).
  • A condition where the small bowel (part of your gut) does not work properly (paralytic ileus).
  • Itching rash (hives).
  • Withdrawal symptoms in babies born to mothers who have used hydromorphone (see "Pregnancy and breastfeeding" in section 2).
  • Sleep apnoea (breathing pauses during sleep). Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

How to store it

Palladone SR capsules Keep this medicine out of the sight and reach of children. Do not use any capsules after the expiry date which is stated on the blister and carton after "EXP". The expiry date refers to the last day of that month. Do not store your capsules above 25°C. Store in the original package. Do not take your capsules if they are broken or crushed as this can be dangerous and can cause serious problems such as overdose. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.

Contents of the pack and other information

What Palladone SR capsules contain The active ingredient is hydromorphone hydrochloride. Each capsule contains 2 mg, 4 mg or 8 mg of hydromorphone hydrochloride. The other ingredients are:

  • Microcrystalline cellulose
  • Hypromellose
  • Ethylcellulose
  • Colloidal anhydrous silica
  • Dibutyl sebacate
  • Gelatin

• • • • •

Sodium laurilsulfate Shellac Propylene glycol Titanium dioxide (E171) Iron oxide (E172)

The capsules also contain the following colourants: 2 mg capsule – Quinoline yellow (E104) 4 mg capsule – Erythrosine (E127) and indigo carmine (E132) 8 mg capsule – Erythrosine (E127) What Palladone SR capsules look like and the contents of the pack The capsules have a hard gelatin shell containing spherical pellets. The capsules are marked HCR followed by the strength (e.g. 2, 4 etc.) and are coloured as follows: 2 mg – yellow/ white, 4 mg – pale blue/clear, 8 mg – pink/clear. In each box there are 56 capsules. Marketing Authorisation Holder and Manufacturer The capsules are made by Bard Pharmaceuticals Limited for the marketing authorisation holder Napp Pharmaceuticals Limited, both at Cambridge Science Park, Milton Road, Cambridge CB4 0GW, UK. This leaflet is also available in large print, Braille or as an audio CD. To request a copy, please call the RNIB Medicine Information line (free of charge) on: 0800 198 5000 You will need to give details of the product name and reference number. These are as follows: Product name: Palladone SR prolonged-release capsules Reference number: 16950/0051 This leaflet was last revised in November 2025. ® Palladone, NAPP and the NAPP logo are registered trade marks. © 2011-2025 Napp Pharmaceuticals Limited.

Frequently asked questions about Palladone SR capsules 8 mg

How do I take Palladone SR capsules 8 mg?

Palladone SR capsules 8 mg comes as capsule containing 8mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Palladone SR capsules 8 mg?

The active substance in Palladone SR capsules 8 mg is hydromorphone hydrochloride.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Palladone SR capsules 8 mg, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Palladone SR capsules 8 mg without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Hydromorphone hydrochloride (6 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

For the relief of severe pain in cancer.

Palladone SR capsules are indicated in adults and children aged 12 years and above.

4.2. Posology and method of administration

Posology

Prior to starting treatment with opioids, a discussion should be held with patients to put in place a strategy for ending treatment with hydromorphone in order to minimise the risk of addiction and drug withdrawal syndrome (see section 4.4).

Transferring patients between oral and parenteral hydromorphone

Switching patients from parental hydromorphone to oral hydromorphone should be guided by the sensitivity of the individual patient. The oral starting dose should not be overestimated (for oral bioavailability see section 5.2).

Adults and children aged 12 years and above

Palladone SR capsules should be used at 12 hourly intervals. The dosage is dependent upon the severity of the pain and the patient's previous history of analgesic requirements. 4 mg of hydromorphone has an efficacy approximately equivalent to 30 mg of morphine sulphate given orally. A patient presenting with severe pain should normally be started on a dosage of 4 mg Palladone SR capsules 12 hourly. Increasing severity of pain may require increased dosage of hydromorphone to achieve the desired relief.

Elderly and patients with renal impairment

The elderly and patients with renal impairment should be dose titrated with Palladone SR capsules in order to achieve adequate analgesia. It should be noted, however, that these patients may require a lower dosage to achieve adequate analgesia.

Patients with hepatic impairment

Contraindicated.

Paediatric population

Not recommended.

Method of administration

For oral use.

The capsules can be swallowed whole or opened and their contents sprinkled on to cold soft food.

Treatment goals and discontinuation:

Before initiating treatment with Palladone SR capsules, a treatment strategy including treatment duration and treatment goals, and a plan for end of the treatment, should be agreed together with the patient, in accordance with pain management guidelines. During treatment, there should be frequent contact between the physician and the patient to evaluate the need for continued treatment, consider discontinuation and to adjust dosages if needed. When a patient no longer requires therapy with hydromorphone, it may be advisable to taper the dose gradually to prevent symptoms of withdrawal. In absence of adequate pain control, the possibility of hyperalgesia, tolerance and progression of underlying disease should be considered (see section 4.4).

Duration of treatment:

Hydromorphone should not be used longer than necessary.

4.3. Contraindications

Hydromorphone is contra-indicated in patients with:

• Known hypersensitivity to hydromorphone or any of the excipients

• Severe respiratory depression with hypoxia and/or hypercapnia

• Severe chronic obstructive lung disease

• Severe bronchial asthma

• Paralytic ileus

• Acute abdomen

• Coma

• Hepatic impairment

• Concurrent administration of monoamine oxidase inhibitors or within 2 weeks of discontinuation

4.4. Special warnings and precautions for use

Hydromorphone should be administered with caution in the debilitated elderly and in patients with:

• Severely impaired respiratory function

• Sleep apnoea

• CNS depressants co-administration (see below and section 4.5)

• Head injury, intracranial lesions or increased intracranial pressure, reduced level of consciousness of uncertain origin

• Hypotension with hypovolaemia

• Pancreatitis

• Hypothyroidism

• Toxic psychosis

• Prostatic hypertrophy

• Adrenocortical insufficiency (e.g., Addison's disease)

• Severely impaired renal function

• Severely impaired hepatic function

• Alcoholism

• Delirium tremens

• Convulsive disorders

• Constipation

• Shock or reduced respiratory reserve.

Respiratory depression

The major risk of opioid excess is respiratory depression.

Opioids may cause sleep-related breathing disorders including central sleep apnoea (CSA) and sleep-related hypoxemia. Opioid use may increase the risk of CSA in a dose-dependent manner in some patients. Opioids may also cause worsening of pre-existing sleep apnoea (see section 4.8). In patients who present with CSA, consider decreasing the total opioid dosage.

Risk from concomitant use of sedative medicines such as benzodiazepines (and other CNS depressants):

Concomitant use of Palladone SR capsules and sedative medicines such as benzodiazepines or related drugs may result in sedation, respiratory depression, coma and death. Because of these risks, concomitant prescribing with these sedative medicines should be reserved for patients for whom alternative treatment options are not possible. If a decision is made to prescribe Palladone SR capsules concomitantly with sedative medicines, the lowest effective dose should be used, and the duration of treatment should be as short as possible. The patients should be followed closely for signs and symptoms of respiratory depression and sedation. In this respect, it is strongly recommended to inform patients and their caregivers to be aware of these symptoms (see section 4.5).

Sleep-related breathing disorders

Opioids can cause sleep-related breathing disorders including central sleep apnoea (CSA) and sleeprelated hypoxemia. Opioid use increases the risk of CSA in a dose-dependent manner (see section 4.8).

In patients who present with CSA, consider decreasing the total opioid dosage

Tolerance and Opioid Use Disorder (abuse and dependence)

Tolerance, physical and/or psychological dependence may develop upon repeated administration of opioids such as hydromorphone.

Repeated use of Palladone SR can lead to Opioid Use Disorder (OUD). A higher dose and longer duration of opioid treatment can increase the risk of developing OUD. Abuse or intentional misuse of Palladone SR may result in overdose and/or death. The risk of developing OUD is increased in patients with a personal or a family history (parents or siblings) of substance use disorders (including alcohol use disorder), in current tobacco users or in patients with a personal history of other mental health disorders (e.g. major depression, anxiety and personality disorders).

Before initiating treatment with Palladone SR and during the treatment, treatment goals and a discontinuation plan should be agreed with the patient (see section 4.2). Before and during treatment the patient should also be informed about the risks and signs of OUD. If these signs occur, patients should be advised to contact their physician.

Patients will require monitoring for signs of drug-seeking behaviour (e.g. too early requests for refills). This includes the review of concomitant opioids and psycho-active drugs (like benzodiazepines). For patients with signs and symptoms of OUD, consultation with an addiction specialist should be considered.

Palladone SR capsules are not recommended for pre-operative use or in the first 24 hours post-operatively. After this time they should be used with caution, following abdominal surgery.

Palladone SR capsules should not be used where there is the possibility of paralytic ileus occurring. Should paralytic ileus be suspected or occur during use, Palladone SR capsules should be discontinued.

Prolonged release opioids should not be used for acute post-operative pain owing to the increased risk of persistent post-operative opioid use (PPOU) and opioid-induced ventilatory impairment (OIVI).​

Patients about to undergo cordotomy or other pain relieving surgical procedures should not receive Palladone SR capsules for 24 hours prior to surgery. If further treatment with Palladone SR capsules is indicated then the dosage should be adjusted to the new post-operative requirement.

Drug dependence, tolerance and potential for abuse

For all patients, prolonged use of this product may lead to drug dependence (addiction), even at therapeutic doses. The risks are increased in individuals with current or past history of substance misuse disorder (including alcohol misuse) or mental health disorder (e.g. major depression).

Additional support and monitoring may be necessary when prescribing for patients at risk of opioid misuse.

A comprehensive patient history should be taken to document concomitant medications, including over-the-counter medicines and medicines obtained on-line, and past and present medical and psychiatric conditions.

Patients may find that treatment is less effective with chronic use and express a need to increase the dose to obtain the same level of pain control as initially experienced. Patients may also supplement their treatment with additional pain relievers. These could be signs that the patient is developing tolerance. The risks of developing tolerance should be explained to the patient.

Overuse or misuse may result in overdose and/or death. It is important that patients only use medicines that are prescribed and do not give this medicine to anyone else.

Patients should be closely monitored for signs of misuse, abuse or addiction.

The clinical need for analgesic treatment should be reviewed regularly.

Drug withdrawal syndrome

Prior to starting treatment with any opioids, a discussion should be held with patients to put in place a withdrawal strategy for ending treatment with hydromorphone.

Drug withdrawal syndrome may occur upon abrupt cessation of therapy or dose reduction. When a patient no longer requires therapy, it is advisable to taper the dose gradually to minimise symptoms of withdrawal. Tapering from a high dose may take weeks to months.

The opioid drug withdrawal syndrome is characterised by some or all of the following: restlessness, lacrimation, rhinorrhoea, yawning, perspiration, chills, myalgia, mydriasis and palpitations. Other symptoms may also develop including irritability, agitation, anxiety, hyperkinesia, tremor, weakness, insomnia, anorexia, abdominal cramps, nausea, vomiting, diarrhoea, increased blood pressure, increased respiratory rate or heart rate.

If women take this drug during pregnancy there is a risk that their newborn infants will experience neonatal withdrawal syndrome.

Hyperalgesia

Hyperalgesia may be diagnosed if the patient on long-term opioid therapy presents with increased pain. This might be qualitatively and anatomically distinct from pain related to disease progression or to breakthrough pain resulting from development of opioid tolerance. Pain associated with hyperalgesia tends to be more diffuse than the pre-existing pain and less defined in quality. Symptoms of hyperalgesia may resolve with a reduction of opioid dose.

The prolonged release capsules may be opened and their contents sprinkled onto soft cold food.

The content (pellets) of the prolonged release capsules must be swallowed whole, and not broken, chewed or crushed. The administration of broken, chewed or crushed hydromorphone pellets leads to a rapid release and absorption of a potentially fatal dose of hydromorphone (see section 4.9).

Concomitant use of alcohol and Palladone SR capsules may increase the undesirable effects of Palladone SR capsules; concomitant use should be avoided.

Abuse of oral dosage forms by parenteral administration can be expected to result in serious adverse events, which may be fatal.

Opioids, such as hydromorphone, may influence the hypothalamic-pituitary-adrenal or –gonadal axes. Some changes that can be seen include an increase in serum prolactin, and decreases in plasma cortisol and testosterone. Clinical symptoms may be manifest from these hormonal changes.

4.5. Interaction with other medicinal products and other forms of interaction

Central nervous system (CNS):

The concomitant use of opioids with sedative medicines such as benzodiazepines or other drugs that depress the CNS increases the risk of sedation, respiratory depression, coma and death because of additive CNS depressant effects. The dose and duration of concomitant use should be limited (see section 4.4). Drugs which depress the CNS include, but are not limited to: other opioids, anxiolytics, hypnotics and sedatives (including benzodiazepines), anaesthetics (e.g. barbiturates), antiemetics, antidepressants, antipsychotics (e.g. phenothiazines), antihistamines and alcohol.

The concomitant use of opioids and gabapentinoids (gabapentin and pregabalin) increases the risk of opioid overdose, respiratory depression and death.

Co-administration with monoamine oxidase inhibitors or within 2 weeks of discontinuation of their use is contraindicated (see section 4.3).

Alcohol may enhance the pharmacodynamic effects of Palladone SR capsules; concomitant use should be avoided.

4.6. Fertility, pregnancy and lactation

Pregnancy

There are no well-controlled studies of hydromorphone in pregnant women.

Hydromorphone should not be used in pregnancy unless clearly necessary.

Palladone SR capsules are not recommended during pregnancy and labour due to impaired uterine contractility. Regular use in pregnancy may cause drug dependence in the foetus, leading to withdrawal symptoms in the neonate.

If opioid use is required for a prolonged period in pregnant women, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.

Administration during labour may depress respiration in the neonate and an antidote for the child should be readily available.

Breast-feeding

Administration to nursing women is not recommended as hydromorphone is excreted into breast milk in low amounts and may cause respiratory depression in the infant.

Fertility

Non clinical toxicology studies in rats have not shown any effects on male or female fertility or sperm parameters.

4.7. Effects on ability to drive and use machines

Hydromorphone may cause drowsiness and patients should not drive or operate machinery if affected.

This medicine can impair cognitive function and can affect a patient's ability to drive safely. This class of medicine is in the list of drugs included in regulations under 5a of the Road Traffic Act 1988. When prescribing this medicine, patients should be told:

▪ The medicine is likely to affect your ability to drive.

▪ Do not drive until you know how the medicine affects you.

▪ It is an offence to drive while you have this medicine in your body over a specified limit unless you have a defence (called the 'statutory defence').

▪ This defence applies when:

▪ The medicine has been prescribed to treat a medical or dental problem; and

▪ You have taken it according to the instructions given by the prescriber and in the information provided with the medicine.

▪ Please note that it is still an offence to drive if you are unfit because of the medicine (i.e. your ability to drive is being affected).”

Details regarding a new driving offence concerning driving after drugs have been taken in the UK may be found here: https://www.gov.uk/drug-driving-law

4.8. Undesirable effects

Hydromorphone may cause constipation, nausea and vomiting. Constipation may be treated with appropriate laxatives. When nausea and vomiting are troublesome Palladone SR capsules can be readily combined with antiemetics.

The following frequency categories form the basis for classification of the undesirable effects:

Term

Frequency

Very common

≥ 1/10

Common

≥ 1/100 to < 1/10

Uncommon

≥ 1/1,000 to < 1/100

Rare

≥ 1/10,000 to < 1/1,000

Very rare

< 1/10,000

Not known

Cannot be estimated from the available data

Very common

Common

Uncommon

Rare

Very rare

Not known

Immune system disorders

Hypersensitivity (including oropharyngeal swelling);

Anaphylactic reactions

Metabolism and nutrition disorders

Decreased appetite

Psychiatric disorders

Confusional state;

Anxiety;

Insomnia

Agitation;

Depression;

Euphoric mood;

Hallucinations;

Nightmares

Drug dependence (see section 4.4);

Dysphoria

Nervous system disorders

Dizziness;

Somnolence

Headache

Myoclonus;

Tremor;

Paraesthesia

Sedation;

Lethargy

Convulsions;

Dyskinesia;

Hyperalgesia (see section 4.4; Central sleep apnoea syndrome

Eye disorders

Visual impairment

Miosis

Cardiac disorders

Tachycardia

Vascular disorders

Hypotension

Flushing

Respiratory, thoracic and mediastinal disorders

Dyspnoea

Respiratory depression

Gastrointestinal disorders

Constipation;

Nausea

Abdominal pain;

Dry mouth;

Vomiting

Diarrhoea;

Dysgeusia

Paralytic ileus

Hepatobiliary disorders

Hepatic enzymes increased

Skin and subcutaneous tissue disorders

Pruritus

Hyperhidrosis

Rash

Urticaria

Renal and urinary disorders

Urinary retention

Reproductive system and breast disorders

Erectile dysfunction

General disorders and administration site conditions

Asthenia

Drug withdrawal syndrome;

Fatigue;

Malaise;

Peripheral oedema

Drug tolerance;

Drug withdrawal syndrome neonatal

Description of selected adverse reactions

Drug dependence

Repeated use of Palladone SR capsules can lead to drug dependence, even at therapeutic doses. The risk of drug dependence may vary depending on a patient's individual risk factors, dosage, and duration of opioid treatment (see section 4.4).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

Signs of hydromorphone toxicity and overdosage are pin-point pupils, respiratory depression and hypotension. Circulatory failure and somnolence progressing to stupor or deepening coma, pneumonia aspiration, skeletal muscle flaccidity, bradycardia and death may occur in more severe cases. Rhabdomyolysis progressing to renal failure has been reported in opioid overdosage.

Toxic leukoencephalopathy has been observed with hydromorphone overdose.

Patients should be informed of the signs and symptoms of overdose and to ensure that family and friends are also aware of these signs and to seek immediate medical help if they occur.

Treatment of overdosage:

Primary attention should be given to the establishment of a patent airway and institution of assisted or controlled ventilation.

In the case of massive overdosage, administer naloxone intravenously (0.4 to 2 mg for an adult and 0.01 mg/kg body weight for children), if the patient is in a coma or respiratory depression is present. Repeat the dose at 2 minute intervals if there is no response. If repeated doses are required then an infusion of 60% of the initial dose per hour is a useful starting point. A solution of 10 mg made up in 50 ml dextrose will produce 200 micrograms/ml for infusion using an IV pump (dose adjusted to the clinical response). Infusions are not a substitute for frequent review of the patient's clinical state.

Intramuscular naloxone is an alternative in the event IV access is not possible. As the duration of action of naloxone is relatively short, the patient must be carefully monitored until spontaneous respiration is reliably re-established. Naloxone is a competitive antagonist and large doses (4 mg) may be required in seriously poisoned patients. For less severe overdosage, administer naloxone 0.2 mg intravenously followed by increments of 0.1 mg every 2 minutes if required.

Naloxone should not be administered in the absence of clinically significant respiratory or circulatory depression secondary to hydromorphone overdosage. Naloxone should be administered cautiously to persons who are known, or suspected, to be physically dependent on hydromorphone. In such cases, an abrupt or complete reversal of opioid effects may precipitate an acute withdrawal syndrome.

Other supportive measures as indicated by the patient's progress and clinical condition should be considered.

Additional/other considerations:

Consider activated charcoal (50 g for adults, 1g/kg for children), if a substantial amount has been ingested within 1 hour, provided the airway can be protected. It may be reasonable to assume that late administration of activated charcoal may be beneficial for prolonged release preparations; however there is no evidence to support this.

Palladone SR capsules will continue to release and add to the hydromorphone load for up to 12 hours after administration and management of hydromorphone overdosage should be monitored accordingly. Gastric contents may need to be emptied as this can be useful in removing unabsorbed drug, particularly when a prolonged release formulation has been taken.

💬 Ask about this leaflet

Ask anything about Palladone SR capsules 8 mg. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →